-transparent.png){kind=logo}
Of clinically isolated Staphylococcus aureus showing resistance to multiple drugs among penicillins (PCs), cephem antibiotics (CEPs), aminoglycosides (AGs), minocycline (MINO) and fosfomycin (FOM), 64 strains were selected for the determination of MIC. Twenty-one drugs were used for the determination of MIC, with ampicillin (ABPC), cloxacillin (MCIPC), cephalothin (CET), cefazolin (CEZ), cefotiam (CTM), cefuroxime (CXM), cefamandole (CMD), cefotaxime (CTX), ceftizoxime (CZX), cefmenoxime (CMX), cefmetazole (CMZ), cefoxitin (CFX), latamoxef (LMOX), cefotetan (CTT), cefoperazone (CPZ), gentamicin (GM), dibekacin (DKB), tobramycin (TOB), amikacin (AMK), MINO, and FOM. MIC80 of each drug at 10(6) CFU/ml were: ABPC, MCIPC, CEZ, CTM, CXM, CTX, CZX, CMX, CFX, LMOX, CTT, CPZ, GM, DKB and TOB greater than 100 micrograms/ml; CET 50 micrograms/ml; CMD and AMK 25 micrograms/ml; CMZ 12.5 micrograms/ml; FOM 6.25 micrograms/ml; and MINO 0.78 micrograms/ml. The ratio of highly resistant strains with MIC greater than 100 micrograms/ml at 10(6) CFU/ml varied according to drug, and a difference tended to be seen in the degree of influence by resistant factors reflected upon MIC, e.g. drugs for which a high resistance of more than 50% was confirmed were ABPC, CXM, CZX, LMOX and TOB, and 20 approximately 30% MCIPC, CTM, CTX, CMX and CFX. MIC on MCIPC which has a correlation of structural activity with methicillin correlated with cephems (CEPs) resistance to a high degree, but many of the so-called new CEPs showed resistance even to the strains with a low MIC on MCIPC. It was assumed that CEPs resistant strains have multiple drug resistant factors based on the fact that such strains showed multiple drug resistance.(ABSTRACT TRUNCATED AT 250 WORDS)
K Deguchi, and
S Fukayama, and
Y Nishimura, and
N Yokota, and
S Tanaka, and
S Oda, and
Y Matsumoto, and
R Ikegami, and
K Satoh, and
Y Toyonaga
September 1992,
Annals of the Academy of Medicine, Singapore,
K Deguchi, and
S Fukayama, and
Y Nishimura, and
N Yokota, and
S Tanaka, and
S Oda, and
Y Matsumoto, and
R Ikegami, and
K Satoh, and
Y Toyonaga
January 1997,
African journal of medicine and medical sciences,
K Deguchi, and
S Fukayama, and
Y Nishimura, and
N Yokota, and
S Tanaka, and
S Oda, and
Y Matsumoto, and
R Ikegami, and
K Satoh, and
Y Toyonaga
March 1981,
American journal of clinical pathology,
K Deguchi, and
S Fukayama, and
Y Nishimura, and
N Yokota, and
S Tanaka, and
S Oda, and
Y Matsumoto, and
R Ikegami, and
K Satoh, and
Y Toyonaga
July 1982,
The Japanese journal of antibiotics,
K Deguchi, and
S Fukayama, and
Y Nishimura, and
N Yokota, and
S Tanaka, and
S Oda, and
Y Matsumoto, and
R Ikegami, and
K Satoh, and
Y Toyonaga
August 1971,
Rinsho byori. The Japanese journal of clinical pathology,
K Deguchi, and
S Fukayama, and
Y Nishimura, and
N Yokota, and
S Tanaka, and
S Oda, and
Y Matsumoto, and
R Ikegami, and
K Satoh, and
Y Toyonaga
July 1963,
Lancet (London, England),
K Deguchi, and
S Fukayama, and
Y Nishimura, and
N Yokota, and
S Tanaka, and
S Oda, and
Y Matsumoto, and
R Ikegami, and
K Satoh, and
Y Toyonaga
September 1974,
The Journal of antibiotics,
K Deguchi, and
S Fukayama, and
Y Nishimura, and
N Yokota, and
S Tanaka, and
S Oda, and
Y Matsumoto, and
R Ikegami, and
K Satoh, and
Y Toyonaga
April 1986,
Nursing,
K Deguchi, and
S Fukayama, and
Y Nishimura, and
N Yokota, and
S Tanaka, and
S Oda, and
Y Matsumoto, and
R Ikegami, and
K Satoh, and
Y Toyonaga
January 2001,
Connecticut medicine,
K Deguchi, and
S Fukayama, and
Y Nishimura, and
N Yokota, and
S Tanaka, and
S Oda, and
Y Matsumoto, and
R Ikegami, and
K Satoh, and
Y Toyonaga
March 1981,
The Journal of antibiotics,
